No Subacute Ketamine Effect on Reward Processing: Implications for Trial Design

No Subacute Effect of Ketamine on Reward Processing in Healthy Adults

A single-blind, placebo-controlled crossover study published on September 24, 2026, found that ketamine, administered at 0.5 mg/kg via intravenous infusion, does not significantly alter neural reward processing in healthy adults five hours post-administration. Functional magnetic resonance imaging (fMRI) during the Monetary Incentive Delay (MID) task revealed no significant differences in brain activation between ketamine and placebo conditions. This result was consistent across both region-of-interest (ROI) and whole-brain analyses, despite measurable subjective drug effects and expected pharmacokinetic profiles for ketamine and its metabolite norketamine (OpenAlex W7214170867).

Mechanistic Insights: Timing and Population Matter

Ketamine’s effects on brain function are known to be temporally dynamic, with acute dissociative and perceptual changes peaking within the first hours after administration. However, this study provides direct evidence that these effects do not extend to the subacute phase—approximately five hours post-infusion—at least in healthy individuals without baseline reward dysfunction. The lack of association between plasma drug levels, subjective effects, and neural activation during reward processing tasks suggests that ketamine’s impact on reward circuitry may be tightly linked to the acute phase or to populations with altered baseline reward processing, such as those with major depressive disorder (MDD).

This nuance is critical: many clinical trials for mood disorders use reward processing as a biomarker for antidepressant efficacy. The present findings indicate that, in healthy controls, ketamine does not produce subacute changes in reward-related brain activity, challenging assumptions that its neural effects are broadly persistent or generalizable across populations.

Policy and Research Implications for Mood Disorder Trials

The absence of subacute neural effects in healthy adults has immediate implications for the design of ketamine trials targeting mood disorders. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) increasingly expect precise mechanistic endpoints and population-specific data in investigational new drug (IND) applications. This study suggests that future trials should:

• Prioritize acute-phase imaging and behavioral assessments if targeting neural reward processing as a primary endpoint.
• Recruit clinical populations with demonstrable reward processing deficits, rather than healthy volunteers, for mechanistic studies.
• Consider the timing of outcome measures and the pharmacokinetic profile of ketamine and its metabolites when interpreting results.

A non-obvious implication is that negative findings in healthy controls may help de-risk clinical trial protocols by clarifying when and in whom to expect neural changes, potentially reducing false negatives and improving statistical power in patient populations.

Risks, Unknowns, and Methodological Limitations

While the study was well-controlled, several limitations warrant caution. The sample size (n=28) may not detect small effect sizes, and the findings may not generalize to other dosing regimens, administration routes, or time points beyond five hours post-infusion. Moreover, healthy participants may not exhibit the baseline reward dysfunction necessary to observe ketamine’s therapeutic effects. The lack of robust associations between pharmacokinetic measures and neural activation also raises questions about the sensitivity of current imaging paradigms to detect subtle drug effects outside the acute window.

Importantly, these results do not rule out subacute or longer-term effects in clinical populations, nor do they address potential behavioral or subjective changes that might occur independently of neural activation patterns measured by fMRI.

Looking Forward: Refining the Target and the Timeline

This study adds nuance to the growing literature on ketamine’s neural action profile, emphasizing the importance of timing and population selection in both basic and clinical research. For researchers and sponsors, the findings underscore the need to align trial endpoints with the known temporal dynamics of ketamine’s effects and to focus on populations most likely to benefit. For regulators and policymakers, the results support a more tailored approach to evaluating mechanistic evidence in the context of psychedelic and rapid-acting antidepressant development.

As the field moves toward greater precision in trial design and regulatory expectations, studies like this one will be essential in distinguishing signal from noise—ensuring that future research is both scientifically rigorous and clinically relevant.

How we research: This article was written and reviewed by Dr. Alex R. Levine, PhD (Neuroscience), on 2026-09-25. Primary data and methodology were sourced directly from the published study and the OpenAlex database.